GENENTA SCIENCE
Genenta Science is a biotechnology company that develops gene transfer therapy for the treatment of cancer tumors. The company is based in Milan, Italy.
GENENTA SCIENCE
Industry:
Biotechnology Clinical Trials Genetics Health Care
Founded:
2014-01-01
Address:
Milano, Lombardia, Italy
Country:
Italy
Website Url:
http://www.genenta.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
33.94 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Qianzhang Investment
Qianzhang Investment investment in Series C - Genenta Science
Club degli Investitori
Club degli Investitori investment in Series C - Genenta Science
Club degli Investitori
Club degli Investitori investment in Series B - Genenta Science
Mediobanca Banca di Credito Finanziario S.p.A.
Mediobanca Banca di Credito Finanziario S.p.A. investment in Series A - Genenta Science
Official Site Inspections
http://www.genenta.com Semrush global rank: 4.92 M Semrush visits lastest month: 1.75 K
- Host name: calvin.dnshigh.com
- IP address: 86.107.36.46
- Location: Voineasa Romania
- Latitude: 45.4167
- Longitude: 23.95
- Timezone: Europe/Bucharest
- Postal: 247750
More informations about "Genenta Science"
ABOUT US | Genenta science
Genenta was founded in 2014 as a spin-off of the San Raffaele Hospital in Milan.. The co-founders are: Pierluigi Paracchi, Chairman and CEO; Luigi Naldini, M.D., Ph.D., a pioneer in …See details»
Genenta science | Genenta science
Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers.. Genenta’s first in class product candidate is …See details»
Genenta Science - Crunchbase Company Profile & Funding
Organization. Genenta Science . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Genenta Science is a …See details»
LEADERSHIP | Genenta science
M.D. Chief Medical Officer Head of Development. Carlo Russo is a senior biotech executive with vast experience in research & development in large pharma companies and biotech industry with extensive expertise in clinical …See details»
Genenta Science (Nasdaq: GNTA) - LinkedIn
Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first ...See details»
Investor Relations | Genenta Science
Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include combination with immune checkpoint inhibitors. Our treatments are designed as …See details»
Genenta Science - Overview, News & Similar companies - ZoomInfo
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science …See details»
Genenta and Anemocyte announce a collaboration for the
2 days ago Genenta’s treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other …See details»
Genenta Science SpA - Drug pipelines, Patents, Clinical trials
2 days ago Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors. Genenta’s …See details»
Genenta Science Company Profile - Office Locations, Competitors …
Genenta Science $33.92 m in total funding,. See insights on Genenta Science including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Genenta and Anemocyte announce a collaboration for the …
3 days ago Anemocyte established Cell Banks and Plasmids for Viral Vector ProductionMILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), …See details»
SCIENTIFIC BOARD | Genenta science
Ph.D., M.D. Co-Founder Executive Scientific Board Chairman. Dr. Luigi Naldini is Professor of Cell and Tissue Biology and Cell and Gene Therapy at the Vita-Salute San Raffaele University School of Medicine in Milan, and Director of …See details»
Genenta Announces €20 million ($21.9M) Financing To Expand …
MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today …See details»
Genenta Science - Contacts, Employees, Board Members
Genenta Science is a biotechnology company that develops gene transfer therapy for the treatment of cancer tumors. ... Experience the new Crunchbase, powered by AI . Experience …See details»
Genenta and Anemocyte announce a collaboration - News
3 days ago Milan, Italy and New York, USA – May 7, 2025 – Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a …See details»
Genenta Science S.p.A.: Shareholders, Shareholding Structure ...
Apr 23, 2025 Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene …See details»
GENENTA TECHNOLOGY | Genenta science
GENENTA TECHNOLOGY. Cell-based technology for safe tumor treatments. Il tuo browser non supporta la riproduzione del video. Our proprietary technology centers on a transgene …See details»
Genenta Science - Funding, Financials, Valuation & Investors
Genenta Science is registered under the ticker NASDAQ:GNTA . Their stock opened with $11.50 in its Dec 15, 2021 IPO. Stock Symbol NASDAQ:GNTA ; Valuation at IPO $208.4M; Money …See details»
OUR PIPELINE | Genenta science
Temferon is a lenti-virus immuno therapy based on hematopoietic stem progenitor cell enabling controlled and targeted IFNa expresssion within the tumor microenvironment (TME) of solid …See details»
Share ownership Genenta Science S.p.A. - MarketScreener.com
2 days ago Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene …See details»